


Changes in albuminuria and the effect of finerenone on cardiovascular outcomes: Insights from FINEARTS-HF



Finnian R. Mc Causland¹; Muthiah Vaduganathan¹; Brian L. Claggett¹; Akshay S. Desai¹; Pardeep S. Jhund²; Martina M. McGrath¹; Katja Rohwedder³; Flaviana Amarante³; Meike Brinker³; Patrick Schloemer³; Carolyn SP Lam⁴; Michele Senni⁵; Sanjiv J. Shah⁶; Adriaan A. Voors⁷; Faiez Zannad⁸; Bertram Pitt⁹; John JV McMurray²; Scott D. Solomon¹

¹Brigham & Women's Hospital, Harvard Medical School, Boston, MA; ²University of Glasgow, Glasgow, Scotland, United Kingdom; ³Bayer, Germany/US; ⁴National Heart Centre Singapore & Duke-National University of Singapore, Singapore; ⁵University of Milano-Bicocca ASST Papa Giovanni XXIII Hospital, Bergamo, Italy; ⁶Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States; ⁷University of Groningen, Groningen, Netherlands; ⁸University of Lorraine, Nancy, France; ⁹University of Michigan, Ann Arbor, Michigan, United States

INTRODUCTION

- Albuminuria is a potent predictor of adverse cardiovascular and kidney outcomes.^{1,2}
- Albuminuria reduction accounted for a modest proportion of the effect of finerenone in reducing adverse cardiovascular outcomes among patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).³
- Whether this is similar among patients with heart failure (HF) is not clear.

AIM

- Explore the proportion of the treatment effect of mediated by the change in urine albumin/creatinine ratio from baseline to 3 months among participants of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF⁴; a randomized trial of finerenone vs. placebo among patients with HF with mildly reduced or preserved ejection fraction.

METHODS

- We performed a post hoc mediation analysis of 5,086 participants with available data from the FINEARTS-HF trial.
- Using accelerated failure time models, we explored the proportion of risk reduction mediated by a change in urine albumin/creatinine ratio (UACR; log-transformed and >30% decline) between baseline and 3 months on the subsequent risk of: 1) the composite of cardiovascular death or first HF event; 2) first worsening HF event.

METHODS




Figure 1. Directed acyclic graph illustrating the proposed mediation model. In the upper panel, the effect of the exposure (finerenone vs. placebo) on clinical outcomes is represented as a solid line between the two boxes (Total Effect).

In the lower panel, the treatment effect is considered as two parts: 1) the effect that is independent of the mediator (Direct Effect), and 2) the effect mediated by a reduction in UACR (Indirect Effect).

The percent mediated represents the percent of the total effect of finerenone on the outcome that is due to the effect mediated by the reduction in UACR.

RESULTS

Table 1. Mediation analyses according to changes in UACR from baseline to month 3

Relative mean survival (95%CI) (log-UACR as mediator)					
	Total Effects	Direct Effects	Indirect Effects	% Direct	% Mediated
CV death or first Heart Failure event	1.20 (1.04, 1.37)	1.13 (0.98, 1.29)	1.06 (1.04, 1.09)	66 (-31, 85)	34 (15, 131)
Heart Failure event	1.28 (1.08, 1.52)	1.19 (1.01, 1.41)	1.07 (1.04, 1.11)	71 (14, 86)	29 (14, 86)
Relative mean survival (95%CI) (≥30% vs. <30% decline in UACR as mediator)					
	Total Effects	Direct Effects	Indirect Effects	% Direct	% Mediated
CV death or first Heart Failure event	1.20 (1.04, 1.37)	1.17 (1.01, 1.34)	1.03 (1.01, 1.05)	85 (42, 95)	15 (5, 58)
Heart Failure event	1.28 (1.08, 1.52)	1.24 (1.06, 1.47)	1.03 (1.01, 1.05)	90 (66, 97)	10 (3, 34)




Fig 2. Kaplan-Meier analyses showing CV composite (A) and HF events (B) after 3 months, according to randomized treatment and 30% decline in UACR from baseline to 3 months

CONCLUSIONS

- Among participants of FINEARTS-HF, those who experienced >30% decline in UACR (vs. ≤30%) had lower risks of adverse cardiovascular outcomes.
- Despite relatively low levels of baseline albuminuria, early changes in UACR accounted for a modest proportion of the effect of finerenone on reducing cardiovascular outcomes.
- These findings highlight the importance of measuring UACR among patients with heart failure.

REFERENCES

- Consortium WG for the CP, Appel LJ, Grams M, Woodward M, Harris K, Arima H, et al.: Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes. *JAMA* 330: 1266–1277, 2023
- Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al.: Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. *Am J Kidney Dis* 75: 84–104, 2020
- Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, et al.: Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. *Ann. Intern. Med.* 176: 1606–1616, 2023
- Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al.: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *N. Engl. J. Med.* 391: 1475–1485, 2024

CONTACT INFORMATION

Finnian Mc Causland: fmccausland@bwh.harvard.edu

FUNDING

FINEARTS-HF was sponsored by Bayer-AG